Oncology

 
Measuring Biomarkers
at Every Stage
of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels is enabling new options for diagnostics and treatment in cancer research.

Simoa assays can be used to monitor cancer risk, identify early stage cancers and discriminate between benign and malignant cells. Simoa biomarkers can be used prognostically to predict disease outcome, predict progression free survival and monitor reoccurrence. Assays can also be used to monitor sensitivity to therapy and to aid in treatment decisions.

Latest News

03.15
We were honored to be able to speak about the promise of immuno-oncology (IO) therapeutics at this year’s Molecular Med Tri-Con conference and the 12th Annual Biomarkers Congress.
02.15
Tumor biomarkers act as important contextual cues or signals of cancer status.

Request to Learn More